Thu, January 6, 2022
Wed, January 5, 2022
Tue, January 4, 2022
Mon, January 3, 2022
Sun, January 2, 2022
Fri, December 31, 2021
Thu, December 30, 2021
Wed, December 29, 2021
Tue, December 28, 2021
Mon, December 27, 2021
Thu, December 23, 2021
Wed, December 22, 2021
Tue, December 21, 2021
Mon, December 20, 2021

Michael Schmitz Maintained (BPMC) at Strong Buy with Increased Target to $122 on, Jan 3rd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-122-on-jan-3rd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Michael Schmitz of Guggenheim, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $120 to $122 on, Jan 3rd, 2022.

Michael has made no other calls on BPMC in the last 4 months.



There are 2 other peers that have a rating on BPMC. Out of the 2 peers that are also analyzing BPMC, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $111 on, Friday, October 29th, 2021


This is the rating of the analyst that currently disagrees with Michael


  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021

Publication Contributing Sources